Cuộc họp báo cáo kết quả kinh doanh Quý 3/2026 của COMPASS Pathways (CMPS): NDA COMP360 và kế hoạch ra mắt năm 2027
Cuộc họp công bố kết quả kinh doanh quý 3 năm 2026 của COMPASS Pathways đã đề cập đến hồ sơ NDA cho COMP360, triển vọng ra mắt sản phẩm điều trị TRD trong nửa đầu năm 2027 và số dư tiền mặt 444 triệu USD của công ty.
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.